1	(	(	-LRB-	_	2	punct	_
2	Reuters	reuters	NNP	_	11	nsubj	11:A0
3	)	)	-RRB-	_	2	punct	_
4	-	-	:	p2=HYPH	2	punct	_
5	GlaxoSmithKline	glaxosmithkline	NNP	p2=NN	2	conj	_
6	and	and	CC	_	5	cc	_
7	Danish	danish	JJ	p2=NNP	9	amod	_
8	biotech	biotech	NN	p2=JJ	9	nn	_
9	company	company	NN	_	10	nn	_
10	Genmab	genmab	NNP	_	5	conj	_
11	said	say	VBD	pb=say.01	0	root	_
12	disappointing	disappointing	JJ	_	13	amod	_
13	results	result	NNS	_	25	nsubj	25:A0=PAG
14	from	from	IN	_	13	prep	_
15	a	a	DT	_	16	det	_
16	study	study	NN	_	14	pobj	_
17	on	on	IN	_	16	prep	_
18	treating	treat	VBG	pb=treat.03	17	pcomp	_
19	relapsed	relapse	VBN	p2=VBD|pb=relapse.01	20	amod	_
20	lymphoma	lymphoma	NN	p2=NNS	18	dobj	18:A1=PPT;19:A1=PPT
21	with	with	IN	_	18	prep	18:AM-MNR
22	their	their	PRP$	_	24	poss	_
23	ofatumumab	ofatumumab	JJ	p2=NN	24	amod	_
24	drug	drug	NN	_	21	pobj	_
25	meant	mean	VBD	pb=mean.01	11	ccomp	11:A1=PPT
26	it	it	PRP	_	27	nsubj	_
27	was	be	VBD	pb=be.01	25	ccomp	25:A1=PPT
28	unlikely	unlikely	JJ	_	27	acomp	27:A2=PRD
29	they	they	PRP	_	31	nsubj	31:A0=PAG
30	would	would	MD	_	31	aux	31:AM-MOD
31	seek	seek	VB	pb=seek.01	27	ccomp	27:A1=PPT
32	its	its	PRP$	_	34	poss	_
33	regulatory	regulatory	JJ	_	34	amod	_
34	approval	approval	NN	_	31	dobj	31:A1=PPT
35	.	.	.	_	11	punct	_

1	A	a	DT	_	9	det	_
2	head	head	NN	_	6	hmod	_
3	-	-	HYPH	_	6	hyph	_
4	to	to	IN	_	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	head	head	NN	_	7	nn	_
7	phase	phase	NN	_	9	nn	_
8	III	iii	CD	p2=NNP	9	num	_
9	study	study	NN	_	23	nsubj	25:A0=PAG;23:A1=PAG
10	of	of	IN	_	9	prep	_
11	ofatumumab	ofatumumab	NN	p2=NNS	10	pobj	_
12	and	and	CC	_	11	cc	_
13	another	another	DT	_	14	det	_
14	drug	drug	NN	_	11	conj	_
15	to	to	TO	_	16	aux	_
16	fight	fight	VB	pb=fight.01	14	infmod	_
17	the	the	DT	_	22	det	_
18	fast	fast	RB	_	20	hmod	_
19	-	-	HYPH	_	20	hyph	_
20	growing	grow	VBG	_	22	amod	_
21	blood	blood	NN	_	22	nn	_
22	cancer	cancer	NN	_	16	dobj	16:A1=COM
23	failed	fail	VBD	pb=fail.01	0	root	_
24	to	to	TO	_	25	aux	_
25	meet	meet	VB	pb=meet.01	23	xcomp	23:A2=PPT
26	the	the	DT	_	27	det	_
27	companies	company	NNS	_	29	poss	_
28	'	'	POS	_	27	possessive	_
29	goals	goal	NNS	_	25	dobj	25:A1=PPT
30	.	.	.	_	23	punct	_

1	Results	result	NNS	_	2	nsubj	2:A0=CAU
2	showed	show	VBD	pb=show.01	23	ccomp	23:A1=PPT
3	no	no	DT	_	5	det	_
4	significant	significant	JJ	_	5	amod	_
5	difference	difference	NN	_	2	dobj	2:A1=PPT
6	in	in	IN	_	5	prep	_
7	progression	progression	NN	_	9	nn	_
8	free	free	JJ	_	9	amod	_
9	survival	survival	NN	_	6	pobj	_
10	(	(	-LRB-	_	11	punct	_
11	PFS	pfs	NNP	p2=NNPS	9	appos	_
12	)	)	-RRB-	_	11	punct	_
13	between	between	IN	_	5	prep	_
14	one	#crd#	CD	_	16	num	_
15	treatment	treatment	NN	_	16	nn	_
16	arm	arm	NN	_	13	pobj	_
17	and	and	CC	_	16	cc	_
18	the	the	DT	_	19	det	_
19	other	other	JJ	_	16	conj	_
20	,	,	,	_	23	punct	_
21	the	the	DT	_	22	det	_
22	companies	company	NNS	_	23	nsubj	23:A0
23	said	say	VBD	pb=say.01	0	root	_
24	in	in	IN	_	23	prep	23:AM-LOC
25	a	a	DT	_	26	det	_
26	statement	statement	NN	_	24	pobj	_
27	late	late	RB	p2=JJ	28	advmod	_
28	on	on	IN	_	23	prep	23:AM-TMP
29	Monday	monday	NNP	_	28	pobj	_
30	.	.	.	_	23	punct	_

1	"	"	``	p2=''	8	punct	_
2	Based	base	VBN	_	8	prep	8:AM-ADV
3	on	on	IN	p2=RP	2	prep	_
4	today	today	NN	_	6	poss	_
5	's	's	POS	_	4	possessive	_
6	results	result	NNS	_	3	pobj	_
7	we	we	PRP	_	8	nsubj	8:A1=PPT;11:A1=PPT
8	are	be	VBP	pb=be.01	27	ccomp	27:A1=PPT
9	unlikely	unlikely	JJ	_	8	acomp	8:A2=PRD
10	to	to	TO	_	11	aux	_
11	move	move	VB	pb=move.01	9	xcomp	_
12	forward	forward	RB	_	11	advmod	11:AM-DIR
13	with	with	IN	_	11	prep	11:AM-MNR
14	a	a	DT	_	16	det	_
15	regulatory	regulatory	JJ	_	16	amod	_
16	filing	filing	NN	_	13	pobj	_
17	,	,	,	_	27	punct	_
18	"	"	''	p2=``	27	punct	_
19	Jan	jan	NNP	_	22	nn	_
20	Van	van	NNP	_	22	nn	_
21	De	de	NNP	_	22	nn	_
22	Winkel	winkel	NNP	_	27	nsubj	27:A0
23	,	,	,	_	22	punct	_
24	Genmab	genmab	NNP	_	26	nn	_
25	chief	chief	JJ	p2=NN	26	amod	_
26	executive	executive	NN	_	22	appos	_
27	said	say	VBD	pb=say.01	0	root	_
28	in	in	IN	_	27	prep	27:AM-LOC
29	the	the	DT	_	30	det	_
30	statement	statement	NN	_	28	pobj	_
31	.	.	.	_	27	punct	_

1	The	the	DT	_	2	det	_
2	companies	company	NNS	_	3	nsubj	3:A0=PAG
3	tested	test	VBD	p2=VBN|pb=test.01	0	root	_
4	PFS	pfs	NNP	p2=NNS	3	dobj	3:A1=LOC
5	,	,	,	_	4	punct	_
6	a	a	DT	_	7	det	_
7	measure	measure	NN	_	4	appos	_
8	of	of	IN	_	7	prep	_
9	the	the	DT	_	10	det	_
10	health	health	NN	_	8	pobj	_
11	of	of	IN	_	10	prep	_
12	a	a	DT	_	13	det	_
13	person	person	NN	_	11	pobj	14:A0
14	taking	take	VBG	pb=take.01	13	partmod	_
15	a	a	DT	_	16	det	_
16	treatment	treatment	NN	_	14	dobj	14:A1=PPT
17	to	to	TO	_	18	aux	_
18	fight	fight	VB	pb=fight.01	14	advcl	14:AM-PRP
19	a	a	DT	_	20	det	_
20	disease	disease	NN	_	18	dobj	18:A1=COM
21	,	,	,	_	18	punct	_
22	among	among	IN	_	18	prep	18:AM-LOC
23	patients	patient	NNS	_	22	pobj	24:A0=PAG
24	using	use	VBG	pb=use.01	23	partmod	_
25	ofatumumab	ofatumumab	NN	p2=RP	24	dobj	24:A1=PPT
26	(	(	-LRB-	_	29	punct	_
27	Arzerra	arzerra	NNP	_	29	nn	_
28	(	(	-LRB-	_	29	punct	_
29	TM	tm	NNP	_	25	appos	_
30	)	)	-RRB-	_	29	punct	_
31	)	)	-RRB-	_	25	punct	_
32	plus	plus	CC	p2=NN	7	cc	_
33	chemotherapy	chemotherapy	NN	_	7	conj	_
34	versus	versus	IN	p2=FW	33	prep	_
35	rituximab	rituximab	NN	p2=NNP	34	pobj	_
36	plus	plus	CC	_	35	cc	_
37	chemotherapy	chemotherapy	NN	_	35	conj	_
38	for	for	IN	_	35	prep	_
39	the	the	DT	_	40	det	_
40	lymphoma	lymphoma	NN	p2=NNP	38	pobj	_
41	of	of	IN	_	40	prep	_
42	the	the	DT	_	45	det	_
43	B	b	NNP	p2=NN	45	hmod	_
44	-	-	HYPH	_	45	hyph	_
45	cells	cell	NNS	_	41	pobj	46:A1=PPT
46	known	know	VBN	pb=know.01	45	partmod	_
47	as	as	IN	_	46	prep	46:A2=PRD
48	DLBCL	dlbcl	NNP	p2=NN	47	pobj	_
49	.	.	.	_	3	punct	_

1	The	the	DT	_	5	det	_
2	Orcharrd	orcharrd	NNP	p2=JJ	3	nn	_
3	phase	phase	NN	p2=NNP	5	nn	_
4	III	iii	NNP	p2=CD	5	nn	_
5	study	study	NN	p2=VB	6	nsubj	6:A2=PPT;16:A2=PRD
6	involved	involve	VBD	p2=VBN|pb=involve.01	0	root	_
7	447	0	CD	_	8	num	_
8	patients	patient	NNS	_	6	dobj	6:A1=PPT;10:A1=PPT
9	who	who	WP	_	10	nsubj	10:R-A1
10	were	be	VBD	pb=be.01	8	rcmod	_
11	refractory	refractory	JJ	p2=VBG	10	acomp	10:A2=PRD
12	to	to	IN	p2=TO	11	prep	_
13	,	,	,	_	6	punct	_
14	or	or	CC	_	6	cc	_
15	had	have	VBD	_	16	aux	_
16	relapsed	relapse	VBN	p2=JJ|pb=relapse.01	6	conj	_
17	following	follow	VBG	p2=JJ	16	dobj	16:A1=PPT
18	,	,	,	_	22	punct	_
19	first	#ord#	JJ	_	21	hmod	_
20	-	-	HYPH	_	21	hyph	_
21	line	line	NN	_	22	nn	_
22	treatment	treatment	NN	_	17	pobj	_
23	with	with	IN	_	22	prep	_
24	rituximab	rituximab	NN	p2=NNP	23	pobj	_
25	in	in	IN	_	24	prep	_
26	combination	combination	NN	_	25	pobj	_
27	with	with	IN	_	26	prep	_
28	a	a	DT	_	30	det	_
29	chemotherapy	chemotherapy	NN	_	30	nn	_
30	regimen	regimen	NN	p2=NNS	31	nsubj	31:A0
31	containing	contain	VBG	pb=contain.01	27	pcomp	_
32	anthracycline	anthracycline	NN	p2=RB	31	dobj	31:A1
33	or	or	CC	_	32	cc	_
34	anthracenedione	anthracenedione	NN	p2=JJ	32	conj	_
35	.	.	.	_	6	punct	_

1	Arzerra	arzerra	NNP	p2=NN	4	nsubjpass	4:A1=PRD;15:A1=PPT;17:A1=PPT
2	is	be	VBZ	_	4	aux	_
3	being	be	VBG	_	4	auxpass	_
4	developed	develop	VBN	pb=develop.02	0	root	_
5	under	under	IN	_	4	prep	4:AM-LOC
6	an	an	DT	_	7	det	_
7	agreement	agreement	NN	_	5	pobj	_
8	between	between	IN	_	7	prep	_
9	Genmab	genmab	NNP	_	8	pobj	_
10	and	and	CC	_	9	cc	_
11	GSK	gsk	NNP	p2=NN	9	conj	_
12	and	and	CC	_	4	cc	_
13	is	be	VBZ	_	15	auxpass	_
14	not	not	RB	_	15	neg	15:AM-NEG;17:AM-NEG
15	approved	approve	VBN	p2=JJ|pb=approve.01	4	conj	_
16	or	or	CC	_	15	cc	_
17	licensed	license	VBN	pb=license.01	15	conj	_
18	anywhere	anywhere	RB	_	17	advmod	17:AM-LOC
19	in	in	IN	_	18	prep	_
20	the	the	DT	_	21	det	_
21	world	world	NN	_	19	pobj	_
22	for	for	IN	_	17	prep	17:A2=GOL
23	the	the	DT	_	24	det	_
24	treatment	treatment	NN	_	22	pobj	_
25	of	of	IN	_	24	prep	_
26	DLBCL	dlbcl	NNP	p2=NN	25	pobj	_
27	.	.	.	_	4	punct	_

1	GSK	gsk	NNP	p2=NN	4	nsubj	4:A0
2	and	and	CC	_	1	cc	_
3	Genmab	genmab	NNP	_	1	conj	_
4	said	say	VBD	pb=say.01	0	root	_
5	dose	dose	NN	p2=VB	6	nn	_
6	interruptions	interruption	NNS	_	9	nsubj	_
7	and	and	CC	_	6	cc	_
8	delays	delay	NNS	_	6	conj	_
9	due	due	JJ	p2=IN	4	ccomp	4:A1=PPT
10	to	to	IN	_	9	prep	_
11	infusion	infusion	NN	_	12	nn	_
12	reactions	reaction	NNS	_	10	pobj	_
13	and	and	CC	_	4	cc	_
14	increased	increase	VBD	p2=VBN|pb=increase.01	16	amod	_
15	serum	serum	NN	p2=RB	16	nn	_
16	creatinine	creatinine	NN	p2=VBN	23	nsubj	23:A0=PAG;14:A1=PPT
17	in	in	IN	_	16	prep	_
18	the	the	DT	_	22	det	_
19	ofatumumab	ofatumumab	NN	p2=JJ	22	nn	_
20	plus	plus	CC	p2=IN	19	cc	_
21	chemotherapy	chemotherapy	NN	_	19	conj	_
22	arm	arm	NN	_	17	pobj	_
23	required	require	VBD	p2=VBN|pb=require.01	4	conj	_
24	further	far	JJ	p2=RB	25	amod	_
25	analysis	analysis	NN	_	23	dobj	23:A1=PPT
26	.	.	.	_	23	punct	_

1	This	this	DT	_	2	det	_
2	discussion	discussion	NN	_	5	nsubjpass	5:A1=PPT
3	is	be	VBZ	_	5	auxpass	_
4	now	now	RB	_	5	advmod	5:AM-TMP
5	closed	close	VBN	p2=JJ|pb=close.01	0	root	_
6	.	.	.	_	5	punct	_

1	We	we	PRP	_	2	nsubj	2:A0=PAG
2	welcome	welcome	VBP	pb=welcome.01	0	root	_
3	comments	comment	NNS	_	2	dobj	2:A1=PPT
4	on	on	IN	_	3	prep	_
5	our	our	PRP$	_	6	poss	_
6	articles	article	NNS	_	4	pobj	_
7	for	for	IN	_	6	prep	_
8	a	a	DT	_	10	det	_
9	limited	limited	JJ	_	10	amod	_
10	period	period	NN	_	7	pobj	_
11	after	after	IN	_	10	prep	_
12	their	their	PRP$	_	13	poss	_
13	publication	publication	NN	_	11	pobj	_
14	.	.	.	_	2	punct	_

